A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
Public ClinicalTrials.gov record NCT02994927. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.
Study identification
- NCT ID
- NCT02994927
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 331 participants
Conditions and interventions
Conditions
Interventions
- Avacopan Drug
- Prednisone Drug
- Cyclophosphamide Drug
- Rituximab Biological
- Azathioprine Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2017 (Actual)
- Primary completion
- Sep 7, 2019 (Actual)
- Completion
- Nov 1, 2019 (Actual)
- Last update posted
- Mar 24, 2025
2017 – 2019
United States locations
- U.S. sites
- 41
- U.S. states
- 27
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Huntsville | Alabama | 35801 | — |
| Clinical Trial Site | Phoenix | Arizona | 85012 | — |
| Clinical Trial Site | Phoenix | Arizona | 85032 | — |
| Clinical Trial Site | Los Angeles | California | 90048 | — |
| Clinical Trial Site | Santa Monica | California | 90404 | — |
| Clinical Trial Site | Aurora | Colorado | 80045 | — |
| Clinical Trial Site | Washington D.C. | District of Columbia | 20007 | — |
| Clinical Trial Site | Daytona Beach | Florida | 32117 | — |
| Clinical Trial Site | Tampa | Florida | 33612 | — |
| Clinical Trial Site | Atlanta | Georgia | 30322 | — |
| Clinical Trial Site | Meridian | Idaho | 83605 | — |
| Clinical Trial Site | Chicago | Illinois | 60637 | — |
| Clinical Trial Site | Indianapolis | Indiana | 46202 | — |
| Clinical Trial Site | Kansas City | Kansas | 66160 | — |
| Clinical Trial Site | Lexington | Kentucky | 40536 | — |
| Clinical Trial Site | Shreveport | Louisiana | 71101 | — |
| Clinical Trial Site | Baltimore | Maryland | 21224 | — |
| Clinical Trial Site | Boston | Massachusetts | 02114 | — |
| Clinical Trial Site | Boston | Massachusetts | 02118 | — |
| Clinical Trial Site | Ann Arbor | Michigan | 48109 | — |
| Clinical Trial Site | Minneapolis | Minnesota | 55414 | — |
| Clinical Trial Site | Rochester | Minnesota | 55905 | — |
| Clinical Trial Site | St Louis | Missouri | 63110 | — |
| Clinical Trial Site | Great Neck | New York | 11021 | — |
| Clinical Trial Site | Mineola | New York | 11501 | — |
| Clinical Trial Site | New York | New York | 10021 | — |
| Clinical Trial Site | New York | New York | 10032 | — |
| Clinical Trial Site | Chapel Hill | North Carolina | 27599 | — |
| Clinical Trial Site | Greenville | North Carolina | 27834 | — |
| Clinical Trial Site | Winston-Salem | North Carolina | 27103 | — |
| Clinical Trial Site | Cleveland | Ohio | 44195 | — |
| Clinical Trial Site | Columbus | Ohio | 43210 | — |
| Clinical Trial Site | Duncansville | Pennsylvania | 16635 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Trial Site | Pittsburgh | Pennsylvania | 15225 | — |
| Clinical Trial Site | Providence | Rhode Island | 02903 | — |
| Clinical Trial Site | Charleston | South Carolina | 29406 | — |
| Clinical Trial Site | Dallas | Texas | 75235 | — |
| Clinical Trial Site | Houston | Texas | 77030 | — |
| Clinical Trial Site | Salt Lake City | Utah | 84132 | — |
| Clinical Trial Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02994927, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02994927 live on ClinicalTrials.gov.